Provided by Tiger Fintech (Singapore) Pte. Ltd.

Krystal Biotech Inc.

147.73
-2.6800-1.78%
Post-market: 147.730.00000.00%18:24 EDT
Volume:322.95K
Turnover:47.96M
Market Cap:4.27B
PE:35.55
High:152.05
Open:150.64
Low:147.14
Close:150.41
Loading ...

Stock Track | Krystal Biotech Plummets 14.64% as Q1 Results Fall Short of Expectations

Stock Track
·
06 May

Krystal Biotech Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
06 May

BUZZ-Krystal Biotech falls on Q1 results miss

Reuters
·
06 May

Krystal Biotech Shares Extend Losses, Last Down 10.7% Premarket

THOMSON REUTERS
·
06 May

Stock Track | Krystal Biotech Plunges 13.73% Pre-Market on Q1 Earnings Miss and Disappointing Sales

Stock Track
·
06 May

Krystal Biotech's Q1 Earnings, Revenue Rise

MT Newswires Live
·
06 May

Krystal Biotech Shares Down 6.9% Premarket After Q1 Results

THOMSON REUTERS
·
06 May

Krystal Biotech Q1 EPS $1.20 Misses $1.32 Estimate, Sales $88.18M Miss $96.24M Estimate

Benzinga
·
06 May

BRIEF-Krystal Biotech Q1 Net Income USD 35.733 Million

Reuters
·
06 May

Krystal Biotech Inc: Q1 EPS $1.20

THOMSON REUTERS
·
06 May

Press Release: Krystal Biotech Announces First Quarter 2025 Financial and Operating Results

Dow Jones
·
06 May

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

Zacks
·
01 May

Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?

Zacks
·
29 Apr

Krystal Biotech Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
29 Apr

Krystal Biotech Inc : H.c. Wainwright Raises Target Price to $240 From $221

THOMSON REUTERS
·
28 Apr

Krystal Biotech price target raised to $240 from $221 at H.C. Wainwright

TIPRANKS
·
28 Apr

Krystal Biotech Gets EU Approval to Market Treatment for Dystrophic Epidermolysis Bullosa

MT Newswires Live
·
28 Apr

Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

GlobeNewswire
·
28 Apr

Krystal Biotech to Present at Upcoming Scientific Conferences

GlobeNewswire
·
24 Apr

Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria

Zacks
·
21 Apr